‘Paradoxical’ placebo response spells Phase 3 failure for Relmada depression drug
A Relmada Therapeutics drug candidate for major depressive disorder failed a Phase 3 clinical trial, but the biotech isn’t giving up on its pill yet. It’s pinning its hopes on additional studies testing the therapy as an additional treatment alongside other depression drugs.